To Study Responsibilities of Sponsors and Investigators in Clinical Trials

Abstract

Clinical trials form the cornerstone of modern medical research by evaluating the safety, efficacy, and quality of new drugs, devices, biologics, and therapeutic strategies. The responsibilities of sponsors and investigators are central to ensuring that these trials are ethical, scientifically robust, and compliant with international regulatory standards. This study examines the key duties, obligations, and expected conduct of both sponsors and investigators based on regulatory frameworks such as ICH-GCP, national drug authorities’ guidance, and institutional policies. Sponsors are responsible for protocol development, regulatory submissions, trial financing, monitoring, investigational product management, and ensuring overall quality assurance. Investigators, on the other hand, oversee subject recruitment, informed consent processes, protocol adherence, safety assessments, data accuracy, documentation, and direct clinical care of participants. Using a descriptive and analytical review methodology, this work synthesizes existing literature and guidelines to present a comprehensive understanding of each party’s responsibilities, areas of collaboration, and operational challenges. The findings highlight the importance of training, communication, monitoring, and ethical compliance in maintaining trial integrity. The study concludes by emphasizing the significance of shared accountability, improved oversight mechanisms, and evolving responsibilities in decentralized and technology-enabled clinical trials. Future exploration is recommended in the dimensions of digital monitoring, AI-driven risk assessments, and harmonized international standards for enhanced global research collaboration.